article thumbnail

Indian healthcare providers and pharma companies speed up to combat TB as drug resistance concerns emerge

AuroBlog - Aurous Healthcare Clinical Trials blog

Indian healthcare providers and pharma companies pace up their efforts with early detection and research for new medicines to combat the spread of tuberculosis as drug resistance concerns emerge. TB is a significant public health threat, with an estimated 10 million annual cases. India shares the highest TB burden with 2.69

article thumbnail

Cloud robotics labs are accelerating drug discovery and development

Pharmaceutical Technology

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Remote-controlled robotic labs.

Drugs 311
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma companies boost drug prices to start year, but hikes lag inflation

Bio Pharma Dive

Analysts noted hundreds of wholesale price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years.

article thumbnail

The pharma company of the future

World of DTC Marketing

So far this year he has received well over $200,000 from just about every pharma company in the U.S. It’s well known that Mitch has argued against any pharma pricing reform so obviously money does buy politicians. Pharma companies have argued that they need profit to develop new drugs but that’s a canard.

article thumbnail

Takeda ends deal with Finch as bumpy ride continues for microbiome drugs

Bio Pharma Dive

The pharma company terminated a collaboration that could’ve netted the biotech about $350 million. It’s the latest in a string of recent setbacks for microbiome drug developers.

Drugs 242
article thumbnail

Sanofi reveals setback for cancer drug acquired in Synthorx buyout

Bio Pharma Dive

Disappointing study results have led the French pharma company to take a $1.6 billion impairment charge and plan new early-stage trials for a drug executives once called a potential “foundation” for newer immunotherapy combinations.

Drugs 200
article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. Most drugs used here are prescribed off-label, and experts say pharmaceutical companies remain hesitant to conduct clinical trials studying gender-affirming care.

Drugs 360